Judy L. Schmidt, MD, FACP is triple board certified in
Internal Medicine, Hematology, and Medical Oncology. She received her Hematology / Medical Oncology training at the Mayo Clinic from 1985 to 1988.
Dr. Schmidt has been a very active member of ASCO (American Society of Clinical Oncology) including numerous positions associated with Medicare and Quality Cancer Care. In 1999, she was invited by ASCO to testify in Washington, DC for a senate subcommittee on Quality Cancer Care, hosted by Senators Diane Feinstein and Connie Mack.
Dr. Schmidt's Hematology / Oncology Montana clinic also helped ASCO develop the parameters by which Quality Cancer Care is now measured. She was a Beta member of the ASCO Quality Oncology Practice Initiative (QOPI) participating in the development of the Quality Cancer Care QOPI standard measures of oncology practice quality. More than 700 Medical Oncology practices in the United States now measure their Oncology practice Quality via QOPI standards.
Dr. Schmidt and her head nurse, Joni Landes RN OCN, received the Professionals of the Year award for quality patient care in 1999 from
Coping Magazine. She also received the Mayo Clinic's award for Quality Cancer Care in 2004.
Dr. Schmidt has provided litigation support services to attorneys for Plaintiff and Defense for over 20 years. She has been retained approximately 40 times and has been an expert Medical Witness for 18 medical malpractice cases since 2010. Dr. Schmidt has reviewed cases for Medical Malpractice Attorneys in Alaska, Arizona, Connecticut, Illinois, Missouri, Montana, New York, Texas and the United Kingdom.
Areas of Expertise:
- Delayed Diagnosis of Cancer
- Failure to Follow Established Clinical Guidelines
- Adverse Drug Side Effects
- Failure to Follow Chemotherapy and Radiation Therapy Guidelines
- Informed Consent
- Analysis of Medical Errors on Patient Quality of Life
View Dr. Schmidt's Consulting Profile.
The cause of platelet agglutination in thrombotic thrombocytopenic purpura has been an enigma. Current evidence indicates that the interaction of platelets with a platelet-aggregating factor or unusually large multimers of factor VIII:von Willebrand factor, or both, may cause the abnormal platelet agglutination. Recent success in the treatment of thrombotic thrombocytopenic purpura with intravenous infusion of immunoglobulin suggests that the abnormal platelet agglutination in thrombotic thrombocytopenic purpura may reflect a deficiency of immunoglobulins that normally inhibit platelet-aggregating factors or large multimers of factor VIII:von Willebrand factor.
Thromboembolism (TE) is a well-known complication in neurosurgical patients and in patients with brain tumors. Estimates of postoperative TE range from 25 to 33% in general surgical patients and from 45 to 70% in patients who have undergone total hip replacement.1 The incidence of deep venous thrombosis (DVT) and pulmonary embolism in neurosurgical patients is similar to that in high-risk surgical patients. The incidence of DVT ranges from 9 to 50% and of fatal pulmonary embolism from 1.5 to 3%.2 The incidence of TE in patients with glioma varies from 36.7% in patients who receive no antithrombotic prophylaxis to 10% in those who receive intermittent pneumatic compression to the calves.3 The current study was undertaken to explore, in patients with high-grade glioma, the associations between TE and factors potentially related to an increased or decreased risk of occurrence of TE.
